Expert Opinion on Pharmacotherapy

Article	Citations
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	36
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children	35
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	33
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	32
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	31
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	30
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	29
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B	28
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases	27
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	25
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	22
The pharmacological treatment and management of hyperhidrosis	22
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	22
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	21
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	20
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	20
How useful is chemotherapy for atypical and anaplastic meningiomas?	20
Current treatment options for Mycobacterium marinum cutaneous infections	20
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	19
Momelotinib in myelofibrosis	19
Zanubrutinib for the treatment of chronic lymphocytic leukemia	18
Selecting optimal therapy in systemic mastocytosis: current state and future directions	18
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	15
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	15
Correction	15

Pharmacotherapeutic options in pediatric obesity: an urgent call for further research	15
Rise and fall of decongestants in treating nasal congestion related diseases	14
The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?	14
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	14
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	14
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	14
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	13
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	13
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	13
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation	13
Treating pediatric aggressive behaviors and comorbid conditions	13
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	13
Tirzepatide for overweight and obesity management	12
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	12
Upadacitinib in Crohn’s disease	12
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	12
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	12
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	12
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	12
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	12
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	12
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	11
An update on current pharmacotherapy for vulvar cancer	11
Approved medications for opioid use disorder : current update	11
An evaluation of the pharmacotherapeutic options for the treatment of adult phimosis. A systematic review of the evidence	11
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	11
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson’s disease treatment?	11
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	11
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	11
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	11
Correction	11
Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review	11
Current pharmacological solutions for Behçet’s syndrome	11
Current advancements in pharmacotherapy for cancer cachexia	11
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	10
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	10
Advances with androgen deprivation therapy for prostate cancer	10
Recent progress in the use of pharmacotherapy for endometrial cancer	10
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	10
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	10
Modern pharmacotherapy guidance for treating alcohol use disorders	10
Evidence-based prescribing of medications for ADHD: where are we in 2023?	10
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	10
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	10
Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	10
Use of glucagon-like polypeptide 2 analogs for intestinal failure	10
Current and emerging COX inhibitors for treating postoperative pain following oral surgery	10
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	10
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	10
Drug treatment strategies for eosinophilic esophagitis in adults	10

Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	9
Simnotrelvir as a potential treatment for COVID-19	9
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	9
Pharmaceutical advances in the treatment of gastric adenocarcinoma	9
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	9
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	9
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	9
Pharmacological management of pituitary adenomas – what is new on the horizon?	9
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	9
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	9
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	9
An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease	9
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	9
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	9
The role of sulfonylureas in the treatment of type 2 diabetes	9
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	9
Advances in the pharmacotherapeutic management of refractory peptic ulcers	9
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	9
Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients	8
Recent advances in the pharmacotherapeutic management of diabetic kidney disease	8
Current status of intracavernosal injection therapy in erectile dysfunction	8
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	8
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	8
An update on the pharmacological management of acne vulgaris: the state of the art	8
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	8
Reassessing the role of aspirin in patients with coronary artery disease	8
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	8
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	8
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	8
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	8
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome	8
Migraine in multiple sclerosis patients: potential links and treatment approach	8
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	8
An overview of emergency pharmacotherapy for priapism	8
The management of cardiovascular disease risk in patients with rheumatoid arthritis	8
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	8
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	7
Advances in the pharmacological management of acute myeloid leukemia in adults	7
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	7
Advances in pharmacotherapy for bronchiectasis in adults	7
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	7
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	7
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	7
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	7
Addressing the long-term risks of administering antenatal steroids	7
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	7
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	7
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes	7
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	7
Guidance for the pharmacological management of COVID-19 in the emergency setting	7
Identifying the challenges for successful pharmacotherapeutic management of sarcopenia	7
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	7
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	7
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	7
Upadacitinib in Crohn’s disease: needs more insight	7
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	7
Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease	7
Promising therapies for the treatment of acromegaly	7
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	7
Sodium–glucose cotransporter 2 inhibitors for the management of type 2 diabetes	7
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	7
Recently approved and emerging drug options for migraine prophylaxis	7
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	7
How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?	7
An update on antifungal resistance in dermatophytosis	7
Glasdegib for the treatment of acute myeloid leukemia	7
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	7
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	7
Risk management of medication errors: a novel conceptual framework	7
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	7
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	7
Pharmacological management of migraine: current strategies and future directions	7
An update on the pharmacotherapy of gout	7
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	7
Evaluating upadacitinib for the treatment of psoriatic arthritis	7
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	7
Pharmacological treatment for children with constipation: present and future	7
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	7
Polypharmacology of carbonic anhydrase inhibitors and activators	6
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	6

A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	6
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	6
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	6
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	6
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	6
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer	6
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	6
Novel pharmacotherapy for drug-induced immune hemolytic anemia	6
Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	6
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	6
State-of-the-art and emerging antivirals for chronic hepatitis B infection	6
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	6
The evolving atopic dermatitis management landscape	6
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	6
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	6
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	6
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	6
Pharmacological management of heart failure: a patient-centred approach	6
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	6
Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections	6
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	6
The pharmacological management of alcohol-related cirrhosis: what’s new?	6
Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs	6
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	6
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	6
The pharmacological management of treatment-resistant depression: what does the future hold?	6
Advances in non-hormonal pharmacotherapy for the treatment of male infertility: the role of inositols	6
Paxlovid as a potential treatment for long COVID	6
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	6
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	6
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	6
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	6
A large-scale database study for the prescription status of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, in Japan	6
How far are we from an approved drug for nonalcoholic steatohepatitis?	6
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	6
Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection	5
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine	5
Doravirine/islatravir for the treatment of HIV	5
The latest advances in the pharmacological management of endometriosis	5
Valbenazine for the treatment of chorea associated with Huntington’s disease	5
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	5
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis	5
The first five years of SARS-CoV-2: inpatient treatment updates and future directions	5
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4	5
Montelukast as a potential treatment for COVID-19	5
Current factor IX replacement options for hemophilia B and the challenges ahead	5
Liposomal drug formulations for treatment of hematological malignancies	5
An evaluation of the available pharmacotherapy for the treatment of hirsutism	5
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	5
Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions	5
Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin’s lymphoma?	5
Efficacy and safety of pitolisant in children above 6 years with narcolepsy	5
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)	5
Ivosidenib in acute myeloid leukemia	5
Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence	5
Management of non-alcoholic fatty liver disease in patients with sarcopenia	5
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	5
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	5
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	5
An update on inclisiran for the treatment of elevated LDL cholesterol	5
Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults	5
What are the challenges in the pharmacotherapeutic management of male genital tuberculosis?	5
An update on the pharmacotherapy of osteoporosis	5
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature	5
Perspectives on the currently available pharmacotherapy for wet macular degeneration	5
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes	5
What are the main considerations when prescribing pharmacotherapy for Parkinson’s disease?	5
What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism?	5
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	5
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	5
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	5